Trademarkia Logo

Canada

C$
CRESCENT SHAPES DESIGN
FORMALIZED

on 4 Jun 2025

Last Applicant/ Owned by

Camurus AB

Rydbergs torg 4SE-224 84 Lund

SE

Serial Number

2403446 filed on 26th Mar 2025

CRESCENT SHAPES DESIGN

Trademark usage description

pharmaceutical preparations; pharmaceutical preparations for injection; pharmaceutical preparation for subcutaneous injection; pharmaceutical preparat Read More

Vienna Information


1 . 7 . 6

Crescent moon, half-moonCroissant, demi-lune

1 . 7 . 19

Several crescents or half-moonsPlusieurs croissants ou demi-lunes

25 . 5 . 3

Backgrounds divided into two, diagonallyFonds partagés en deux en oblique

29 . 1 . 3

GreenVert

Classification Information


Class [005]
Pharmaceutical preparations; pharmaceutical preparations for injection; pharmaceutical preparation for subcutaneous injection; pharmaceutical preparations for the treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for the treatment of neuroendocrine tumours; pharmaceutical preparations for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for the treatment of esophageal bleeding; pharmaceutical preparations for metabolic disorders; pharmaceutical preparations for the treatment of acromegaly; pharmaceutical preparations for the treatment of polycystic liver disease; pharmaceutical preparations for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for the treatment of respiratory distress syndrome; pharmaceutical preparations for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations intended to block growth hormone.


Classification kind code

12

Class [010]
Devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; devices for administration of pharmaceuticals for the treatment of tumours; devices for administration of pharmaceuticals for the treatment of carcinoid tumours; devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; devices for administration of pharmaceuticals for the treatment of esophageal bleeding; devices for administration of pharmaceuticals for metabolic disorders; devices for administration of pharmaceuticals for the treatment of acromegaly; devices for administration of pharmaceuticals for the treatment of polycystic liver disease; devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for the treatment of metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; pens for administration of pharmaceuticals for the treatment of tumours; pens for administration of pharmaceuticals for the treatment of carcinoid tumours; pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; pens for administration of pharmaceuticals for the treatment of esophageal bleeding; pens for administration of pharmaceuticals for metabolic disorders; pens for administration of pharmaceuticals for the treatment of acromegaly; pens for administration of pharmaceuticals for the treatment of polycystic liver disease; pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; pens for administration of pharmaceuticals intended to block growth hormone; devices for subcutaneous administration of pharmaceuticals; devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of injection fluids; devices for injection of injection depot; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; pens for subcutaneous administration of pharmaceuticals; pens for parenteral administration of pharmaceuticals; pens for injection of pharmaceutical depots; pens for subcutaneous injection of pharmaceutical depot; pens for parenteral injection of pharmaceutical depot; pens for injection of injection fluids; pens for injection of injection depot; pens for injections; pens for medical uses.


Classification kind code

12

Mark Details


Serial Number

2403446

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 257
on 5th Jun 2025
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 4th Jun 2025
Created
Submitted for opposition 31
on 4th Jun 2025
Formalized
Submitted for opposition 30
on 26th Mar 2025
Filed
Submitted for opposition 228
on 26th Mar 2025
International Registration